List of Mirati Therapeutics patents

List of Mirati Therapeutics patents

List of Applied Materials patents

List of Ameriwood Industries patents

List of Invacare Corporation patents

Investors in PlayVS

Employee benefits venture capital investors

Patents where

Current Assignee

Name

is

Mirati Therapeutics

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 11492351 MTA-cooperative PRMT5 inhibitors	Patent 11492351 was granted and assigned to Mirati Therapeutics on November, 2022 by the United States Patent and Trademark Office.	Mirati Therapeutics	Mirati Therapeutics		United States Patent and Trademark Office	11492351	November 8, 2022
	‌ US Patent 11479551 MTA-cooperative PRMT5 inhibitors		Mirati Therapeutics	Mirati Therapeutics		United States Patent and Trademark Office	11479551	October 25, 2022
	‌ US Patent 10266542 EZH2 inhibitors	Patent 10266542 was granted and assigned to Mirati Therapeutics on April, 2019 by the United States Patent and Trademark Office.	Mirati Therapeutics	Mirati Therapeutics		United States Patent and Trademark Office	10266542	April 23, 2019
	‌ US Patent 11485738 Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors	Patent 11485738 was granted and assigned to Mirati Therapeutics on November, 2022 by the United States Patent and Trademark Office.	Mirati Therapeutics	Mirati Therapeutics		United States Patent and Trademark Office	11485738	November 1, 2022
	‌ US Patent 9809541 LSD1 inhibitors	Patent 9809541 was granted and assigned to Mirati Therapeutics on November, 2017 by the United States Patent and Trademark Office.	Mirati Therapeutics	Mirati Therapeutics		United States Patent and Trademark Office	9809541	November 7, 2017
	‌ US Patent 10233152 LSD1 inhibitors	Patent 10233152 was granted and assigned to Mirati Therapeutics on March, 2019 by the United States Patent and Trademark Office.	Mirati Therapeutics	Mirati Therapeutics		United States Patent and Trademark Office	10233152	March 19, 2019
	‌ US Patent 10059668 LSD1 inhibitors	Patent 10059668 was granted and assigned to Mirati Therapeutics on August, 2018 by the United States Patent and Trademark Office.	Mirati Therapeutics	Mirati Therapeutics		United States Patent and Trademark Office	10059668	August 28, 2018
	‌ US Patent 11220509 Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors	Patent 11220509 was granted and assigned to Mirati Therapeutics on January, 2022 by the United States Patent and Trademark Office.	Mirati Therapeutics	Mirati Therapeutics		United States Patent and Trademark Office	11220509	January 11, 2022
	‌ US Patent 11091495 Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors	Patent 11091495 was granted and assigned to Mirati Therapeutics on August, 2021 by the United States Patent and Trademark Office.	Mirati Therapeutics	Mirati Therapeutics		United States Patent and Trademark Office	11091495	August 17, 2021
	‌ US Patent 12128048 Combination therapies using PRMT5 inhibitors for the treatment of cancer	Patent 12128048 was granted and assigned to Mirati Therapeutics on October, 2024 by the United States Patent and Trademark Office.	Mirati Therapeutics	Mirati Therapeutics		United States Patent and Trademark Office	12128048	October 29, 2024
	‌ US Patent 11890285 Combination therapies	Patent 11890285 was granted and assigned to Mirati Therapeutics on February, 2024 by the United States Patent and Trademark Office.	Mirati Therapeutics	Mirati Therapeutics		United States Patent and Trademark Office	11890285	February 6, 2024
	‌ US Patent 11999753 Tetrahydropyridopyrimidine pan-KRas inhibitors	Patent 11999753 was granted and assigned to Mirati Therapeutics on June, 2024 by the United States Patent and Trademark Office.	Mirati Therapeutics	Mirati Therapeutics		United States Patent and Trademark Office	11999753	June 4, 2024
	‌ US Patent 11702418 SOS1 inhibitors		Mirati Therapeutics	Mirati Therapeutics		United States Patent and Trademark Office	11702418	July 18, 2023

13 results

0 selected

13 results

0 selected